After back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up its long shot biosimilars case against Enbrel maker Amgen.
Author: TNN Correspondent
World Hypertension Day –Neuro Linguistics Programming & its benefits
The author of this article is Amit Pathak, NLP Trainer and Mental Wellness Coach For people above 40, or even less, Hypertension is a dangerous,
Bach Flower Therapy To Heal Mental Health Issues
The author of this article is Mr. Indroneil Mukerjee, Bach flower Therapist. A couple of years ago, Manisha came to me for Bach Flower therapy, having
Charles River lays out $293M to snap up viral vector specialist Vigene, its 2nd M&A deal this year
A few short months after Charles River Laboratories acquired Cognate BioServices, the company is folding yet another CDMO into its cell and gene network, signing more than
Irish health service hit with ‘significant’ ransomware attack
Last Friday, the Irish health service was hit with a ‘significant’ ransomware attack resulting in its IT systems being temporarily shut down to ‘assess [the]
Biogen’s inherited eye disease gene therapy misses primary endpoint
A gene therapy developed by Biogen for the rare inherited eye disease X-linked retinitis pigmentosa (XLRP) has failed to meet the primary endpoint in a
Keytruda wins NICE backing in MSI-H/dMMR colorectal cancer
MSD’s immunotherapy Keytruda has gained UK National Institute for Health and Care Excellence (NICE) backing as a first-line treatment for certain colorectal cancer patients. The
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups. In February, the companies announced that
ACC 2021: Regeneron’s Evkeeza aces triglyceride control, but only in certain patients
Regeneron’s new med Evkeeza already sports an approval in the ultra-rare disease homozygous familial hypercholesterolemia, which is associated with extreme levels of cholesterol. But thanks
ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients
With an approval filing already on the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients